Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia-higher blood glucose levels-that outcomes from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated along with lasting damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can easily be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Around 85-95% of all of diabetics have actually T2DM.
T2DM treatment has actually been revolutionized in the past decade, especially along with the increased usage of Brand-new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies. Nevertheless, substantial unmet requirement remains for products that can easily supply much better glycemic regulate too as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardio disease.
View Finish Report @: http://ift.tt/1ZKK5T5
Other Crucial Points in Report:
The current T2DM in the Asia-Pacific (APAC) market consists of novel products, including Jardiance-a SGLT-2 inhibitor; Victoza-a GLP-1 receptor agonist; and Galvus-a DPP-4 inhibitor.
-Exactly what are the competitive conveniences of the existing novel drugs?
With over 500 energetic pipeline molecules, the majority of of the late-phase investigational drug candidates are being evaluated, featuring improved dosing routines and administration routes, in comparison to currently marketed products and combination therapies.
-Which classes of novel drugs are the majority of prominent within the pipeline?
-Is there solid potential for the pipeline to manage unmet calls for within the T2DM market?
Analysis of clinical trials, because 2006, identified that the failure rates of T2DM molecules were highest in Phase II, at 54%, along with the overall attrition price for T2DM at 82.6%.
-Exactly how do failure rates vary by product phase of development, molecule type, and mechanism of action?
-Exactly how do Various other factors, such as standard trial duration and trial dimension motivate the costs and risks associated along with product development?
Over the 2014-2021 forecast period, the T2DM therapeutics in the APAC markets is expected to enhance in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion.
Inquire prior to Getting Report @ http://ift.tt/1T8WG1U
Reasons to Buy
This report will certainly permit you to-
-Know the clinical context of T2DM by thinking about symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
-Identify the therapeutic strategies, products, and companies that control The most up to date marketed products landscape and realize gaps and places of unmet need.
-Identify Crucial pipeline trends in molecule type, administration route, mechanism of action, and novelty.
-think of market possibilities and potential risks by examining trends in T2DM clinical trial size, duration, and failure price by phase of development, molecule type, and mechanism of action.
-realize the late-phase pipeline molecules that have actually demonstrated solid therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
-Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, and Japan.
Ask for Sample Report @ http://ift.tt/1ZKK7dN
Table of Content: An Overview
2 Introduction 9
2.1 health problem Overview 9
2.2 Classification 9
2.3 Symptoms 10
2.4 Etiology 10
2.five Pathophysiology 11
2.six Epidemiology 13
2.7 Prognosis 13
2.8 Co-morbidities and Complications 14
2.9 Diagnosis 15
2.10 Assessing Treatment Effectiveness 17
2.11 Treatment 17
2.11.1 Non-insulin T2DM Therapies 19
2.11.2 Insulin T2DM Therapies 22
2.12 Treatment Segments 24
2.12.1 Non-insulin therapies 24
2.12.2 Insulin Therapies 39
3 Marketed Products 43
3.1 Overview 43
3.2 Biguanides 44
3.2.1 Metformin 44
3.3 Sulfonylureas 45
3.4 Thiazolidinediones 47
3.4.1 Pioglitazone 47
Ask for Discount on Report @ http://ift.tt/1T8WG1W
3.five GLP-1 receptor agonists 48
3.5.1 Byetta (exenatide) 48
3.5.2 Bydureon (exenatide) 49
3.5.3 Victoza (liraglutide) 50
3.5.4 Lyxumia (lixisenatide) 51
3.5.five Tanzeum (albiglutide) 53
3.5.six Trulicity (dulaglutide) 54
3.six DPP-4 Inhibitors 55
3.6.1 Januvia/Glactiv (sitagliptin) 55
3.6.2 Galvus (vildagliptin) 56
3.6.3 Onglyza (saxagliptin) 57
3.6.4 Trazenta (linagliptin) 58
3.6.five Zafatek (trelagliptin succinate) 59
3.6.six Marizev (omarigliptin) 60
3.7 SGLT-2 Inhibitors 61
3.7.1 Forxiga (dapagliflozin) 61
3.7.2 Invokana (canagliflozin) 62
3.7.3 Jardiance (empagliflozin) 63
3.8 Insulin Therapies 63
3.8.1 Lantus (insulin glargine) 63
3.8.2 Levemir (insulin detemir) 64
3.8.3 Tresiba (insulin degludec) 65
3.8.4 Toujeo/ Lantus XR (insulin glargine) 66
3.9 Marketed Products Heat Maps 67
4 Pipeline 70
4.1 Overview 70
4.2 Pipeline Distribution by phase of Development, Molecule Type and Routine Type 71
4.3 Pipeline Distribution by Molecular Target 72
4.4 Clinical Trial Landscape 79
Purchase Finish Report @ http://ift.tt/1ZKK5Tb
About ReportsWeb:
ReportsWeb.com is a one avoid shop of market research reports and solutions to various companies across the globe. We suggestions our clients in their decision sustain system by aiding them go with the majority of relevant and expenditure Efficient research reports and solutions from various publishers. We give finest in class customer service and our customer sustain group is constantly offered to suggestions you on your research queries.
Contact Us:
Email: sales@reportsweb.com
Call: +1-646-491-9876
